B2B Manufacturing Business ModelA direct B2B manufacturing model selling biochemical inputs to industrial buyers provides durable, contractable demand and repeat orders. This supports predictable production planning and potential long-term customer relationships, which underpin steadier revenue streams if utilization and pricing stabilize.

Industry Exposure: Specialty & Generic DrugsOperating in the specialty and generic drug manufacturing ecosystem links the company to structurally resilient demand for biochemical intermediates. Regulatory and technical complexity in this sector creates barriers that can sustain demand for qualified suppliers over multiple years.

Modest EPS ImprovementReported positive EPS growth suggests some improvement in per-share profitability metrics despite revenue pressure. If sustained, this can reflect operational cost actions or mix changes that improve earnings quality, offering a foundation for gradual recovery in fundamentals.

Bears Say

Highly Leveraged Balance SheetNegative shareholders' equity and an unfavorable debt-to-equity posture are structural weaknesses that constrain capital flexibility. High leverage raises refinancing and covenant risks, increases financial costs, and limits ability to invest in operations or weather demand downturns over the medium term.

Chronic Negative Cash FlowPersistent negative operating and free cash flows undermine the firm's ability to self-fund operations, capital expenditures, and debt service. This structural cash shortfall raises reliance on external financing and heightens insolvency risk unless underlying cash conversion or profitability is restored.

Ongoing Losses And Falling RevenueSustained negative net income, depressed EBIT margins, and declining revenue indicate deep operational and commercial deficiencies. These trends erode scale economics, weaken margins, and make it harder to cover fixed costs, posing a durable headwind to recovery absent material operational change.

Krebs Biochemicals & Industries Ltd. News

Krebs Biochemicals Board Clears Q3 FY2025 Unaudited Results After Clean Review

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) has shared an update. Krebs Biochemicals & Industries Ltd. announced...

23d ago

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. ( ($IN:KREBSBIO) ) just unveiled an update. Krebs Biochemicals & Industries Ltd. has...

2M ago

KREBSBIO FAQ

What was Krebs Biochemicals & Industries Ltd.’s price range in the past 12 months?

Krebs Biochemicals & Industries Ltd. lowest stock price was ₹51.00 and its highest was ₹113.90 in the past 12 months.

What is Krebs Biochemicals & Industries Ltd.’s market cap?

Krebs Biochemicals & Industries Ltd.’s market cap is ₹1.15B.

When is Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date?

Krebs Biochemicals & Industries Ltd.’s upcoming earnings report date is May 26, 2026 which is in 83 days.

How were Krebs Biochemicals & Industries Ltd.’s earnings last quarter?

Krebs Biochemicals & Industries Ltd. released its earnings results on Feb 09, 2026. The company reported -₹1.45 earnings per share for the quarter, missing the consensus estimate of N/A by -₹1.45.

Is Krebs Biochemicals & Industries Ltd. overvalued?

According to Wall Street analysts Krebs Biochemicals & Industries Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Krebs Biochemicals & Industries Ltd. pay dividends?

Krebs Biochemicals & Industries Ltd. does not currently pay dividends.

What is Krebs Biochemicals & Industries Ltd.’s EPS estimate?

Krebs Biochemicals & Industries Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Krebs Biochemicals & Industries Ltd. have?

Krebs Biochemicals & Industries Ltd. has 21,560,587 shares outstanding.

What happened to Krebs Biochemicals & Industries Ltd.’s price movement after its last earnings report?

Krebs Biochemicals & Industries Ltd. reported an EPS of -₹1.45 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.018%.

Which hedge fund is a major shareholder of Krebs Biochemicals & Industries Ltd.?

Currently, no hedge funds are holding shares in IN:KREBSBIO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Krebs Biochemicals & Industries Ltd.

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.